Chemours Company (The) (NYSE:CC) Shares Sold by Thrivent Financial For Lutherans

They now have a $48.00 price target on the specialty chemicals company's stock. As per Friday, August 7, the company rating was upgraded by JP Morgan.

CC has been the topic of a number of other research reports. UBS AG restated a "sell" rating and set a $36.00 target price (up previously from $35.00) on shares of Chemours Company (The) in a research note on Wednesday, June 14th. Analysts are expecting EPS growth rates to be at 107.70% this quarter and EPS estimate for next year reflect 22.36% growth rate. BidaskClub raised Chemours Company (The) from a "hold" rating to a "buy" rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Chemours Company (The) has a consensus rating of Buy and a consensus target price of $40.88.

Chemours Company (NYSE:CC) opened at 44.76 on Friday. Recently, the stock has been noticed trading 1.72% away from the 20-day moving average. The firm has a market capitalization of $7.40 billion, a price-to-earnings ratio of 70.09 and a beta of 3.57. The Stock becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume.

Chemours Company (The) (NYSE:CC) last issued its earnings results on Monday, May 1st.

Last time, the company shocked Wall Street by reporting EPS of $0.75, smashing the consensus of $0.50 per share. The company had revenue of $1.44 billion during the quarter, compared to analysts' expectations of $1.32 billion. Chemours Company (The) had a return on equity of 125.69% and a net margin of 1.91%.

New 'EX' fighting game from Arika showcased at EVO 2017
Everything known about "EX" so far includes it being playable on PS4 and it possibly being released on April Fool's Day 2018. At Evo 2017 , everyone received more confirming news that this brand new fighter will exist in some way, shape or form.

Over the last 5 years, The Chemours Company has averaged a -65.60% YoY EPS growth rate and a -7.50% revenue growth rate. During the same quarter in the previous year, the firm earned $0.06 earnings per share. Equities analysts anticipate that Chemours Company will post $3.31 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, June 15th. Shareholders of record on Wednesday, May 17th were given a $0.03 dividend. This represents a $0.12 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend was Monday, May 15th. Chemours Company (The)'s payout ratio is now 22.22%. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and worldwide copyright legislation.

Among analysts who offered their Analysis on The Chemours Company (CC)-3 analysts issued Buy for the stock, 4 analysts gave Outperform rating, 0 think it's a Hold, 0 issued Underperform, while 1 analyst gave a Sell rating. The stock was sold at an average price of $45.53, for a total transaction of $223,461.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Erich Parker sold 4,908 shares of the business's stock in a transaction that occurred on Tuesday, May 16th. The shares were acquired at an average price of $39.10 per share, for a total transaction of $97,750.00. The disclosure for this sale can be found here. Company insiders own 1.14% of the company's stock.

Barings LLC maintained its stake in Chemours Company (The) (NYSE:CC) during the first quarter, Holdings Channel reports. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company's stock valued at $162,000 after buying an additional 80 shares during the last quarter. Charter Trust Co. increased its stake in Chemours Company (The) by 2.1% in the second quarter. The company had a trading volume of 1,864,132 shares. Ropes Wealth Advisors LLC increased its position in Chemours Company (The) by 82.4% in the first quarter. Advisor Partners LLC now owns 9,821 shares of the specialty chemicals company's stock worth $378,000 after buying an additional 140 shares during the last quarter. Oakbrook Investments LLC acquired a new position in Chemours Company (The) during the first quarter valued at $255,000. Neuberger Berman Group LLC now owns 9,579 shares of the specialty chemicals company's stock worth $369,000 after buying an additional 141 shares during the last quarter. These ratios are important while doing valuation of the company or the shares of the company. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions.

Latest News